Press Releases

NEWTOWN, PA - (NewMediaWire) - May 14, 2024 - Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2024.

“We navigated through the expected tough first quarter environment head-on, and it has not dimmed our optimism for the long-term growth and earning potential of our company. We are confident in our ability to... (continue reading...)

Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate

Significant milestone achieved towards implementation of a commercially validated manufacturing system

Progress across pipeline with planned data readouts for GEO-CM04S1 in multiple trials and Gedeptin® in healthy patient boost trial on track for later this year

Company to host conference call and... (continue reading...)

CONCORD, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AssetMark Financial Holdings, Inc. (NYSE: AMK) released its “AssetMark Monthly Knowledge” Report today.

Company results for the month of April 2024 include:

• Platform assets of $113.7 billion at the end of April, up 17.3% year-over-year.
• Net flows were $696 million in the month of April, up 60.7% year-over-year.
• AssetMark Trust Company client cash was $2.86 billion, down 0.3% year-over-year.
• Number of... (continue reading...)

LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc.

With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on... (continue reading...)

• Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers
• Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN)
• Received $4.3 million in net proceeds from the sale of net operating losses through the New Jersey Technology Business Tax Certificate Transfer Program
• Presented... (continue reading...)